Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity
Key Points
Key points are not available for this paper at this time.
Abstract
Real-life data confirm nabiximols as an effective and well-tolerated treatment option for resistant MSS in clinical practice.
AI에게 질문
Like
Bookmark
Share
AI에게 질문
Like
Bookmark
Share
Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity | Synapse